NO20055307L - Substituerte isokromanforbindelser for behandling av metabolske forstyrrelser, kreft og andre sykdommer - Google Patents
Substituerte isokromanforbindelser for behandling av metabolske forstyrrelser, kreft og andre sykdommerInfo
- Publication number
- NO20055307L NO20055307L NO20055307A NO20055307A NO20055307L NO 20055307 L NO20055307 L NO 20055307L NO 20055307 A NO20055307 A NO 20055307A NO 20055307 A NO20055307 A NO 20055307A NO 20055307 L NO20055307 L NO 20055307L
- Authority
- NO
- Norway
- Prior art keywords
- treatment
- radicals
- compounds
- diseases
- cancer
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- HEBMCVBCEDMUOF-UHFFFAOYSA-N isochromane Chemical class C1=CC=C2COCCC2=C1 HEBMCVBCEDMUOF-UHFFFAOYSA-N 0.000 title 1
- 208000030159 metabolic disease Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- WJRBRSLFGCUECM-UHFFFAOYSA-N hydantoin Chemical compound O=C1CNC(=O)N1 WJRBRSLFGCUECM-UHFFFAOYSA-N 0.000 abstract 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 208000035150 Hypercholesterolemia Diseases 0.000 abstract 1
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 230000004071 biological effect Effects 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- 150000002391 heterocyclic compounds Chemical class 0.000 abstract 1
- 230000037356 lipid metabolism Effects 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 230000026313 regulation of carbohydrate metabolic process Effects 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/34—Oxygen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US46438803P | 2003-04-18 | 2003-04-18 | |
| PCT/US2004/012284 WO2004093809A2 (en) | 2003-04-18 | 2004-04-19 | Substituted isochroman compounds for the treatment of metabolic disorders, cancer and other diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20055307D0 NO20055307D0 (no) | 2005-11-10 |
| NO20055307L true NO20055307L (no) | 2005-12-21 |
Family
ID=33310879
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20055307A NO20055307L (no) | 2003-04-18 | 2005-11-10 | Substituerte isokromanforbindelser for behandling av metabolske forstyrrelser, kreft og andre sykdommer |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20050038098A1 (pt) |
| EP (1) | EP1643993A2 (pt) |
| JP (1) | JP2006523724A (pt) |
| KR (1) | KR20060036896A (pt) |
| CN (1) | CN1774246A (pt) |
| AU (1) | AU2004232326A1 (pt) |
| BR (1) | BRPI0409501A (pt) |
| CA (1) | CA2522759A1 (pt) |
| MX (1) | MXPA05011242A (pt) |
| NO (1) | NO20055307L (pt) |
| RU (1) | RU2005135850A (pt) |
| WO (1) | WO2004093809A2 (pt) |
| ZA (1) | ZA200509355B (pt) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003508391A (ja) | 1999-08-31 | 2003-03-04 | マキシア・ファーマシューティカルズ・インコーポレイテッド | ベンジリデン−チアゾリジンジオン類およびアナログ類ならびに糖尿病の治療におけるその使用 |
| JP2004523571A (ja) * | 2001-03-08 | 2004-08-05 | マキシア・ファーマシューティカルズ・インコーポレイテッド | Ｒｘｒ活性化分子 |
| WO2003016267A1 (en) * | 2001-08-17 | 2003-02-27 | Incyte San Diego Incorporated | Oxime derivatives for the treatment of dyslipidemia and hypercholesteremia |
| US7196108B2 (en) * | 2002-03-08 | 2007-03-27 | Incyte San Diego Inc. | Bicyclic heterocycles for the treatment of diabetes and other diseases |
| US7102000B2 (en) * | 2002-03-08 | 2006-09-05 | Incyte San Diego Inc. | Heterocyclic amide derivatives for the treatment of diabetes and other diseases |
| WO2008065409A2 (en) * | 2006-12-01 | 2008-06-05 | Betagenon Ab | Combination for use in the treatment of cancer, comprising tamoxifen or an aromatase inhibitor |
| UY31952A (es) * | 2008-07-02 | 2010-01-29 | Astrazeneca Ab | 5-metilideno-1,3-tiazolidina-2,4-dionas sustituidas como inhibidores de quinasa pim |
| CN102329192A (zh) * | 2011-09-30 | 2012-01-25 | 山东天一化学股份有限公司 | 溴化苄的合成方法 |
| EA201491749A1 (ru) * | 2012-03-22 | 2015-01-30 | ТРАНСТЕК ФАРМА, ЭлЭлСи | Трис-(гидроксиметил)аминометановые соли низкомолекулярного агониста glp1r, их фармацевтические композиции и применение |
| CN105315223B (zh) * | 2015-11-06 | 2017-08-25 | 河南大学 | 一种高立体和高对映选择性噻唑烷二酮类化合物、其制备方法及应用 |
| US10238655B2 (en) * | 2017-01-23 | 2019-03-26 | Arizona Board Of Regents On Behalf Of Arizona State University | Dihydroindene and tetrahydronaphthalene compounds |
| US10231947B2 (en) * | 2017-01-23 | 2019-03-19 | Arizona Board Of Regents On Behalf Of Arizona State University | Isochroman compounds and methods of use thereof |
| US10238626B2 (en) * | 2017-01-23 | 2019-03-26 | Arizona Board Of Regents On Behalf Of Arizona State University | Therapeutic compounds |
| CN116693521A (zh) * | 2023-05-10 | 2023-09-05 | 五邑大学 | 一种含色酮结构的噻唑烷二酮乙酯类化合物及其制备方法、药物组合物和应用 |
| CN116693520A (zh) * | 2023-05-10 | 2023-09-05 | 五邑大学 | 一种色酮噻唑二酮类化合物及其制备方法、药物组合物和应用 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4051842A (en) * | 1975-09-15 | 1977-10-04 | International Medical Corporation | Electrode and interfacing pad for electrical physiological systems |
| DE2626348C3 (de) * | 1976-06-11 | 1980-01-31 | Siemens Ag, 1000 Berlin Und 8000 Muenchen | Implantierbare Dosiereinrichtung |
| US4383529A (en) * | 1980-11-03 | 1983-05-17 | Wescor, Inc. | Iontophoretic electrode device, method and gel insert |
| IL72684A (en) * | 1984-08-14 | 1989-02-28 | Israel State | Pharmaceutical compositions for controlled transdermal delivery of cholinergic or anticholinergic basic drugs |
| US4713244A (en) * | 1985-08-16 | 1987-12-15 | Bausch & Lomb Incorporated | Sustained-release formulation containing an amino acid polymer with a lower alkyl (C1 -C4) polar solvent |
| US4668506A (en) * | 1985-08-16 | 1987-05-26 | Bausch & Lomb Incorporated | Sustained-release formulation containing and amino acid polymer |
| US4931279A (en) * | 1985-08-16 | 1990-06-05 | Bausch & Lomb Incorporated | Sustained release formulation containing an ion-exchange resin |
| US4971996A (en) * | 1987-03-11 | 1990-11-20 | Kanegafuchi Kagaku Kogyo Kabushiki Kaisha | Hydroxystyrene compounds which are useful as tyrosine kinase inhibitors |
| US5223522A (en) * | 1988-03-08 | 1993-06-29 | Pfizer Inc. | Thiazolidinedione hypoglycemic agents |
| US5330998A (en) * | 1988-03-08 | 1994-07-19 | Pfizer Inc. | Thiazolidinedione derivatives as hypoglycemic agents |
| EP0595868B1 (en) * | 1991-07-22 | 1998-11-25 | Pfizer Inc. | Process for the preparation of (s)-4-[3-(5-methyl-2-phenyl-4-oxazolyl)- 1-hydroxypropyl]bromobenzene |
| US5780676A (en) * | 1992-04-22 | 1998-07-14 | Ligand Pharmaceuticals Incorporated | Compounds having selective activity for Retinoid X Receptors, and means for modulation of processes mediated by Retinoid X Receptors |
| NZ248573A (en) * | 1992-09-10 | 1996-02-27 | Lilly Co Eli | 5-arylmethyl (and methylidene) thiazolidin-4-one derivatives; their preparation and pharmaceutical compositions |
| EP0745063B1 (en) * | 1994-02-17 | 1999-03-24 | American Home Products Corporation | Substituted biphenyl derivatives as phosphodiesterase inhibitors |
| US5691376A (en) * | 1994-02-17 | 1997-11-25 | American Home Products Corporation | Substituted biphenyl derivatives |
| TR199900684T2 (xx) * | 1996-07-08 | 1999-07-21 | Galderma Research & Development, S.N.C. | Apoptoz uyar�c� adamantil t�revleri ve bunlar�n kansere kar�� maddeler olarak kullan�m�. |
| US6262044B1 (en) * | 1998-03-12 | 2001-07-17 | Novo Nordisk A/S | Modulators of protein tyrosine phosphatases (PTPASES) |
| JP2003508391A (ja) * | 1999-08-31 | 2003-03-04 | マキシア・ファーマシューティカルズ・インコーポレイテッド | ベンジリデン−チアゾリジンジオン類およびアナログ類ならびに糖尿病の治療におけるその使用 |
| FR2812876B1 (fr) * | 2000-08-08 | 2002-09-27 | Galderma Res & Dev | Nouveaux composes bi-aromatiques activateurs des recepteurs de type ppar-gamma et leur utilisation dans des compositions cosmetiques ou pharmaceutiques |
| JP2004523571A (ja) * | 2001-03-08 | 2004-08-05 | マキシア・ファーマシューティカルズ・インコーポレイテッド | Ｒｘｒ活性化分子 |
| WO2003016267A1 (en) * | 2001-08-17 | 2003-02-27 | Incyte San Diego Incorporated | Oxime derivatives for the treatment of dyslipidemia and hypercholesteremia |
| JP2005513026A (ja) * | 2001-11-15 | 2005-05-12 | インサイト サン ディエゴ インコーポレイテッド | 高コレステロール血症、異脂肪血症および他の代謝障害；癌、および他の疾患を治療するｎ−置換複素環 |
| AR037714A1 (es) * | 2001-12-06 | 2004-12-01 | Maxia Pharmaceuticals Inc | Derivados de tiazolidinona y oxazolidinona 2-sustituidos para la inhibicion de fosfatasas y el tratamiento de cancer |
| US7196108B2 (en) * | 2002-03-08 | 2007-03-27 | Incyte San Diego Inc. | Bicyclic heterocycles for the treatment of diabetes and other diseases |
| US7102000B2 (en) * | 2002-03-08 | 2006-09-05 | Incyte San Diego Inc. | Heterocyclic amide derivatives for the treatment of diabetes and other diseases |
-
2004
- 2004-04-19 US US10/827,111 patent/US20050038098A1/en not_active Abandoned
- 2004-04-19 WO PCT/US2004/012284 patent/WO2004093809A2/en not_active Ceased
- 2004-04-19 BR BRPI0409501-4A patent/BRPI0409501A/pt not_active Application Discontinuation
- 2004-04-19 RU RU2005135850/04A patent/RU2005135850A/ru not_active Application Discontinuation
- 2004-04-19 KR KR1020057019855A patent/KR20060036896A/ko not_active Withdrawn
- 2004-04-19 EP EP04760074A patent/EP1643993A2/en not_active Withdrawn
- 2004-04-19 AU AU2004232326A patent/AU2004232326A1/en not_active Abandoned
- 2004-04-19 CN CNA2004800103854A patent/CN1774246A/zh active Pending
- 2004-04-19 MX MXPA05011242A patent/MXPA05011242A/es unknown
- 2004-04-19 ZA ZA200509355A patent/ZA200509355B/en unknown
- 2004-04-19 JP JP2006513185A patent/JP2006523724A/ja not_active Withdrawn
- 2004-04-19 CA CA002522759A patent/CA2522759A1/en not_active Abandoned
-
2005
- 2005-11-10 NO NO20055307A patent/NO20055307L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| RU2005135850A (ru) | 2006-06-10 |
| WO2004093809A3 (en) | 2005-04-21 |
| US20050038098A1 (en) | 2005-02-17 |
| CN1774246A (zh) | 2006-05-17 |
| AU2004232326A1 (en) | 2004-11-04 |
| MXPA05011242A (es) | 2006-07-06 |
| WO2004093809A2 (en) | 2004-11-04 |
| BRPI0409501A (pt) | 2006-04-18 |
| JP2006523724A (ja) | 2006-10-19 |
| ZA200509355B (en) | 2007-03-28 |
| CA2522759A1 (en) | 2004-11-04 |
| NO20055307D0 (no) | 2005-11-10 |
| KR20060036896A (ko) | 2006-05-02 |
| EP1643993A2 (en) | 2006-04-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20055307L (no) | Substituerte isokromanforbindelser for behandling av metabolske forstyrrelser, kreft og andre sykdommer | |
| Koppireddi et al. | Novel 2-(2, 4-dioxo-1, 3-thiazolidin-5-yl) acetamides as antioxidant and/or anti-inflammatory compounds | |
| Krivokolysko et al. | New 4-(2-Furyl)-1, 4-dihydronicotinonitriles and 1, 4, 5, 6-Tetrahydronicotinonitriles: synthesis, structure, and analgesic activity | |
| WO2003029223A1 (de) | Substituierte n-(1, 4, 5, 6-tetrahydro-cyclopentapyrazol-3-yl)-derivate, und deren verwendung zur behandlung von krebs | |
| DE19540027A1 (de) | Substituierte Imidazolidin-2,4-dion-Verbindungen als pharmazeutische Wirkstoffe | |
| CY1113654T1 (el) | Αρυλ ουριες ως αναστολεις κινασων | |
| EA200600122A1 (ru) | Производные пиримидина для лечения патологического роста клеток | |
| DE60022207D1 (de) | Benzyliden-thiazolidindione und analoga und ihre verwendung zur behandlung von diabetes | |
| NO20045679L (no) | Nye fysiologik aktive substanser | |
| Saroha et al. | Novel 1, 2, 3-triazole-aurone hybrids as cathepsin B inhibitors: One-pot synthesis, anti-proliferative, and drug modeling studies | |
| CN103664932B (zh) | 一类吲哚接枝噻唑腙类衍生物及其制备方法和对癌细胞微管蛋白聚合的抑制作用 | |
| Bektaş et al. | Design, synthesis, and characterization of some new benzimidazole derivatives and biological evaluation | |
| EP0979823B1 (en) | Novel amide compounds and drugs containing the same | |
| Ottanà et al. | Synthesis and in vitro evaluation of 5-arylidene-3-hydroxyalkyl-2-phenylimino-4-thiazolidinones with antidegenerative activity on human chondrocyte cultures | |
| CA2355243C (en) | Novel 2-(n-cyanoimino)thiazolidin-4-one derivatives | |
| CN111072634B (zh) | 1-取代-3-取代-5-取代酰胺-1h-吲哚类化合物及其制备方法和应用 | |
| Wang et al. | Design, synthesis, and in vitro evaluation of novel 3, 7‐disubstituted coumarin derivatives as potent anticancer agents | |
| EP0363796A1 (de) | Heterocyclische substituierte Alkoxycumarine, Verfahren zu ihrer Herstellung und diese enthaltende therapeutische Mittel | |
| Matyk et al. | Heterocyclic isosters of antimycobacterial salicylanilides | |
| Singh et al. | Benzoxazolyl linked benzylidene based rhodanine and analogs as novel antidiabetic agents: synthesis, molecular docking, and in vitro studies | |
| Manaf et al. | Synthesis, Characterization and antioxidant activities of Semicarbazide and Thiosemicarbazide Derivatives. | |
| AT510456B1 (de) | Thiazolamin-derivate als zelldifferenzierungsbeschleuniger | |
| DE69630799T2 (de) | Pyrimidinderivate | |
| Sondhi et al. | Conventional and microwave-assisted synthesis of imidazole and guanidine derivatives and their biological evaluation | |
| JP2010526045A (ja) | Ｃｄｃ２５ホスファターゼインヒビターとしてのトリアミノピリミジン誘導体 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |